戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ly sensitized SW1736 cells to perifosine and temsirolimus.
2 ine xenograft tumor models were treated with temsirolimus.
3 tinib, lapatinib, bortezomib, sorafenib, and temsirolimus.
4  observed two-sided P value of .003 favoring temsirolimus.
5 ion, adverse events, and pharmacokinetics of temsirolimus.
6 emsirolimus and 160 mg of neratinib/50 mg of temsirolimus.
7 lls high sensitivities to the mTOR inhibitor temsirolimus.
8 or-suppressive effects of the mTOR inhibitor temsirolimus.
9 e inhibition of tumor growth by Ku0063794 or temsirolimus.
10                                              Temsirolimus 15 mg plus IFN 6 MU is the recommended dose
11                     The recommended dose was temsirolimus 15 mg/IFN 6 MU based on dose-limiting toxic
12 e daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75
13 B (bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week), C (bevacizumab 5 mg/k
14  26), or D (sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly).
15 8 years) at 35 centres in the USA were given temsirolimus 25 mg/week, and rituximab 375 mg/m(2) per w
16  group, to receive the combination of either temsirolimus (25 mg intravenously, weekly) or IFN (9 MIU
17  with cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) in 6-week cy
18 d or refractory MCL were eligible to receive temsirolimus 250 mg intravenously every week as a single
19 temsirolimus group also received intravenous temsirolimus (35 mg/m(2) per dose) on days 1 and 8, wher
20              Lipopolysaccharide (1.5 mg/kg), Temsirolimus (5 mg/kg), AICAR (100 mg/kg).
21  onto a multicenter, ascending-dose study of temsirolimus (5, 10, 15, 20, or 25 mg) administered intr
22  the ULN, OS was significantly improved with temsirolimus (6.9 v 4.2 months; P < .002).
23 n due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]).
24 4 months), and 7.4 months for sorafenib plus temsirolimus (90% CI, 5.6 to 7.9 months).
25 0.8 months), 7.6 months for bevacizumab plus temsirolimus (90% CI, 6.7 to 9.2 months), 9.2 months for
26 d, PI(3,5)P(2)-bound closed, and PI(3,5)P(2)/temsirolimus (a rapamycin analog)-bound open states.
27                                              Temsirolimus, a sirolimus analog, eliminated the effect
28                                              Temsirolimus, a specific inhibitor of the mammalian targ
29                        Patients who received temsirolimus alone had longer overall survival (hazard r
30 he response and safety of the combination of temsirolimus (an mTOR inhibitor) and bortezomib in patie
31                                              Temsirolimus, an inhibitor of the mammalian target of ra
32 sible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanc
33 ere identified: 200 mg of neratinib/25 mg of temsirolimus and 160 mg of neratinib/50 mg of temsirolim
34 randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuxim
35 aximum blood concentration was 292 ng/mL for temsirolimus and 37.2 ng/mL for its metabolite sirolimus
36                           The combination of temsirolimus and bevacizumab had substantial activity an
37 ay using the combination of mTORC1 inhibitor temsirolimus and dasatinib in other pediatric cancer ind
38 Xs grown in mice suggest that combination of temsirolimus and dasatinib treatment will be efficacious
39                           Rapamycin analogs, temsirolimus and everolimus, are approved for the treatm
40                           The combination of temsirolimus and IFN has an acceptable safety profile an
41 ting, which were observed at higher doses of temsirolimus and IFN.
42 se and safety profile for the combination of temsirolimus and interferon alfa (IFN) were determined i
43                                   The sum of temsirolimus and sirolimus areas under the concentration
44 ergistic inhibition effect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhib
45 tive mammalian target of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomy
46 me inhibitors (bortezomib), mTOR inhibitors (temsirolimus), and immunomodulatory drugs (lenalidomide)
47                   The activity of sorafenib, temsirolimus, and bevacizumab administered in doublet co
48 g analysis further revealed that everolimus, temsirolimus, and pomalidomide are predicted to target t
49 its analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA approved as mTO
50 methasone, erlotinib, everolimus, gefitinib, temsirolimus, and thalidomide) either had no effect on m
51 ity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rit
52                               Everolimus and temsirolimus are inhibitors of mTOR (mTORi) approved for
53             Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors,
54 evacizumab arms versus the chemotherapy plus temsirolimus arm.
55 3%) and 69.1% (95% CI, 55.1% to 83%) for the temsirolimus arm.
56  CI, 31.5% to 63.2%) for the bevacizumab and temsirolimus arms, respectively (P = .12) and, 28% of pa
57 s knowledge we identified 2-deoxyglucose and temsirolimus as agents that can be added to a parthenoli
58  LDH, OS was not significantly improved with temsirolimus as compared with interferon therapy (11.7 v
59                                 Single-agent temsirolimus at a weekly dose of 75 mg was found to be a
60          Median PFS in patients treated with temsirolimus/bevacizumab (n = 400) versus IFN/bevacizuma
61                                              Temsirolimus/bevacizumab combination therapy was not sup
62                           Patients receiving temsirolimus/bevacizumab reported significantly higher o
63 bjective response rate (27.0% nu 27.4%) with temsirolimus/bevacizumab versus IFN/bevacizumab, respect
64                Incidence of pneumonitis with temsirolimus/bevacizumab was 4.8%, mostly grade 1 or 2.
65 3 adverse events more common (P < .001) with temsirolimus/bevacizumab were mucosal inflammation, stom
66 ral inhibitors of PI3k/mTOR signaling (e.g., temsirolimus, BKM120, AZD8055, PF4708671) and/or cisplat
67          In contrast, mTOR inhibition (e.g., temsirolimus) blocked cisplatin-induced Bmi-1 expression
68 GF1R/IR inhibitor with the rapalog inhibitor temsirolimus broadened the sensitivity of PDAC cells to
69            Consistent with this possibility, temsirolimus, but not Ku0063794, decreased tumor angioge
70 nhibition by the rapamycin derivatives (RDs) temsirolimus (CCI-779) and everolimus (RAD001) in acute
71 ent with the FDA-approved rapamycin analogue temsirolimus (CCI-779) blocks ANDV protein expression an
72                                              Temsirolimus (CCI-779) is a small-molecule inhibitor of
73                  In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mammali
74 OR pathway, in particular the mTOR inhibitor temsirolimus (CCI-779), induce autophagy, which can prom
75                    Compared with the rapalog temsirolimus/CCI-779, WYE-132 elicited a substantially s
76                                              Temsirolimus CSF concentration was 2 ng/mL in one patien
77 with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, be
78 urther study whereas irinotecan-temozolomide-temsirolimus did not.
79     The administration of the mTOR inhibitor temsirolimus, even after established endotoxemia, induce
80                           Those on letrozole/temsirolimus experienced more grade 3 to 4 events (37% v
81 istine and irinotecan (VAC/VI) combined with temsirolimus followed by maintenance therapy versus VAC/
82 nical trial was to prioritize bevacizumab or temsirolimus for additional investigation in rhabdomyosa
83 roup vs 66.8% [57.5-76.2] in the VAC/VI plus temsirolimus group (hazard ratio 0.86 [95% CI 0.58-1.26]
84                              Patients in the temsirolimus group also received intravenous temsirolimu
85 t was overall survival in comparisons of the temsirolimus group and the combination-therapy group wit
86  patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02)
87 ommon grade 3 or worse adverse events in the temsirolimus group were neutropenia (eight [44%] of 18 p
88  87 [58%] of 149 patients in the VAC/VI with temsirolimus group), lymphopenia (83 events in 65 [44%]
89  survival times in the interferon group, the temsirolimus group, and the combination-therapy group we
90 e treatment-related death in the VAC/VI with temsirolimus group, categorised as not otherwise specifi
91 , and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in
92 f 149 were FOXO1 negative in the VAC/VI with temsirolimus group.
93                        Patients who received temsirolimus had a superior EFS compared with bevacizuma
94 d, 28% of patients on bevacizumab and 11% on temsirolimus had progressive disease at 6 weeks.
95              A potential explanation is that temsirolimus has additional effects on the tumor microen
96                                              Temsirolimus has been selected for additional investigat
97                                 Single-agent temsirolimus has significant activity in both diffuse la
98                                 Single-agent temsirolimus has substantial antitumor activity in relap
99                           Both ibrutinib and temsirolimus have shown single-agent activity in patient
100 ) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0.43 [95% CI 0.32-0.58]; medi
101            As compared with interferon alfa, temsirolimus improved overall survival among patients wi
102 a rapamycin ester (cell cycle inhibitor-779, temsirolimus) improves motor performance in a transgenic
103 otherapy combined with either bevacizumab or temsirolimus in advanced endometrial cancer, 213 cases h
104                                              Temsirolimus in combination with chemotherapy has shown
105            Ku0063794 was more effective than temsirolimus in decreasing the viability and growth of R
106  the first report of substantial activity of temsirolimus in lymphomas other than mantle cell lymphom
107 lysis showed improved PFS favoring letrozole/temsirolimus in patients </= age 65 years (9.0 v 5.6 mon
108  antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bo
109 free survival and better tolerability versus temsirolimus in patients with relapsed or refractory man
110                    Ku0063794 was compared to temsirolimus in preclinical models for renal cell carcin
111  the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymph
112        Bortezomib (in the United States) and temsirolimus (in Europe) are currently the only two trea
113                                              Temsirolimus inhibited the phosphorylation of p70S6K, a
114                                              Temsirolimus inhibits mammalian target of rapamycin and
115      The first cohort (n = 6) received 25 mg temsirolimus intravenously once per week.
116                                              Temsirolimus is a mammalian target of rapamycin (mTOR) i
117                                              Temsirolimus is designed for long-term use in patients a
118                           Weekly intravenous temsirolimus is well tolerated in children with recurren
119                                              Temsirolimus is well tolerated in recurrent GBM patients
120 arget of rapamycin (mTOR) inhibitor CCI-779 (temsirolimus) is a recently Food and Drug Administration
121               Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieve
122 ents were randomised to ibrutinib (n=139) or temsirolimus (n=141).
123 mmalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harbori
124 ed to examine the effect of cisplatin and/or temsirolimus on CSCs in vivo.
125 s 1, 8, 15, and 22 in combination with 25 mg temsirolimus on days 1, 8, 15, 22, and 29, for a cycle o
126  assigned to receive bevacizumab on day 1 or temsirolimus on days 1, 8, and 15 of each 21-day treatme
127 patients assigned to irinotecan-temozolomide-temsirolimus, one patient (6%; 95% CI 0.0-16.1) achieved
128             We aimed to test the addition of temsirolimus or dinutuximab to irinotecan-temozolomide i
129 ) to irinotecan and temozolomide plus either temsirolimus or dinutuximab, stratified by disease categ
130 ubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.
131 on of mTORC2 signaling during treatment with temsirolimus or everolimus.
132 ng autophagy, either pharmacologically (with temsirolimus) or by dietary intervention (with trehalose
133 sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines.
134                                              Temsirolimus peak concentration (Cmax), and sirolimus Cm
135             Consequently, the combination of temsirolimus plus CCR4 antagonist, a receptor highly exp
136 ng bevacizumab plus chemotherapy relative to temsirolimus plus chemotherapy.
137                    This study tested whether temsirolimus (previously known as CCI-779), an inhibitor
138                                              Temsirolimus produced an objective response rate of 9.2%
139                                              Temsirolimus reduces the number of aggregates seen in th
140                              The most common temsirolimus-related adverse events of all grades were m
141 revious systemic therapy (anti-angiogenic or temsirolimus; second-line population) were eligible.
142 irolimus showed antitumor activity and 75 mg temsirolimus showed a generally tolerable safety profile
143 d or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg temsiro
144           The combination of cixutumumab and temsirolimus shows clinical activity in patients with sa
145 mary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free sur
146                                  Remarkably, temsirolimus slowed down tumor growth and decreased the
147 ials of the novel targeted agents sunitinib, temsirolimus, sorafenib, and bevacizumab.
148 mall-molecule targeted inhibitors sunitinib, temsirolimus, sorafenib, and the monoclonal antibody bev
149 ithout a reducing dose of intravenous weekly temsirolimus starting at 15 mg/m(2) or 0.5 mg/kg per dos
150                            We confirmed that temsirolimus targeted host mTOR complex 1 (mTORC1) and n
151 trate that the parthenolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of t
152 lower in Caki-1 and 786-O cells treated with temsirolimus than cells treated with Ku0063794.
153                  The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as ant
154 VAC/VI alone and 149 assigned to VAC/VI with temsirolimus), the median age was 6.3 years (IQR 3.0-11.
155                              The addition of temsirolimus to interferon did not improve survival.
156                                       Adding temsirolimus to letrozole did not improve PFS as first-l
157                                  Addition of temsirolimus to VAC/VI did not improve event-free surviv
158 iographic improvement was observed in 36% of temsirolimus-treated patients, and was associated with s
159 is effect was specific to viral proteins, as temsirolimus treatment did not block host protein synthe
160 ataxin-3 mice that were normalized following temsirolimus treatment.
161 ein expression, which were blocked following temsirolimus treatment.
162 perior activity was found with sunitinib and temsirolimus versus cytokines in first-line therapy.
163                                              Temsirolimus was administered in a 250-mg intravenous do
164                                  Intravenous temsirolimus was given at 15 or 25 mg and intravenous bo
165        In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or ref
166             The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor ac
167                                              Temsirolimus was withheld during radiotherapy and for 2
168 randomly assigned to receive 75 or 250 mg of temsirolimus weekly as a 30-minute intravenous infusion.
169 weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa
170 ll carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (wit
171  mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested,
172 mmalian target of rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients.
173          Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent

 
Page Top